BINSA Act

The BINSA Act expands the existing investment screening rules under the Defense Production Act to include the biotechnology sector, specifically covering pharmaceuticals, biological products, and therapeutic compounds. This change aims to prevent U.S. capital from flowing into Chinese companies through licensing, joint ventures, or investments that could transfer critical drug development capabilities and manufacturing know-how. To implement this, the Treasury Department must create specific guidelines within a year that focus on high-risk transactions while explicitly excluding agricultural biotech and basic academic research. Additionally, the Department of Defense is required to submit a report assessing how current investments in China's biotech industry might impact U.S. national security and military readiness.